zBMI long term (> 15 months) · children aged 5 to 11 years
1 finding from 1 review
Body‐mass index (BMI) · children aged 5 to 11 years
1 finding from 1 review
zBMI long term (> 15 months) · children aged 5 to 11 years
1 finding from 1 review
Body‐mass index (BMI) · children aged 5 to 11 years
1 finding from 1 review
zBMI long term (> 15 months) · children aged 5 to 11 years
1 finding from 1 review
Body‐mass index (BMI) · children aged 12 to 18 years
1 finding from 1 review
zBMI long term (> 15 months) · children aged 12 to 18 years
1 finding from 1 review
Body‐mass index (BMI) · children aged 12 to 18 years
1 finding from 1 review
zBMI long term (> 15 months) · children aged 12 to 18 years
1 finding from 1 review
Body‐mass index (BMI) · children aged 12 to 18 years
1 finding from 1 review
zBMI long term (> 15 months) · children aged 12 to 18 years
1 finding from 1 review
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 · adults and children with cystic fibrosis
1 finding from 1 review
FEV1 · adults and children with cystic fibrosis (stable lung disease)
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 (L) · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 (L) · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found